Morgan Stanley’s Foamix Pharmaceuticals Ltd. Ordinary Shares FOMX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2020
Q1
Sell
-1,407,948
Closed -$4.69M 6878
2019
Q4
$4.69M Buy
1,407,948
+1,406,396
+90,618% +$4.47M ﹤0.01% 3267
2019
Q3
$5K Hold
1,552
﹤0.01% 6381
2019
Q2
$4K Sell
1,552
-43,692
-97% -$131K ﹤0.01% 6381
2019
Q1
$169K Buy
45,244
+17,037
+60% +$63.8K ﹤0.01% 5149
2018
Q4
$101K Buy
28,207
+23,207
+464% +$101K ﹤0.01% 5558
2018
Q3
$29K Sell
5,000
-49,580
-91% -$284K ﹤0.01% 6035
2018
Q2
$274K Buy
54,580
+26,203
+92% +$135K ﹤0.01% 5412
2018
Q1
$145K Buy
+28,377
New +$171K ﹤0.01% 5599
2017
Q3
Sell
-20
Closed 6672
2017
Q2
$0 Hold
20
﹤0.01% 6703
2017
Q1
$0 Buy
+20
New +$192 ﹤0.01% 6657
2016
Q4
Sell
-832
Closed -$8K 6606
2016
Q3
$8K Sell
832
-14,565
-95% -$122K ﹤0.01% 6162
2016
Q2
$98K Buy
15,397
+8,147
+112% +$54.1K ﹤0.01% 5253
2016
Q1
$47K Sell
7,250
-14,606
-67% -$94.2K ﹤0.01% 5635
2015
Q4
$177K Sell
21,856
-375
-2% -$2.8K ﹤0.01% 5150
2015
Q3
$163K Buy
22,231
+3,069
+16% +$31.3K ﹤0.01% 5189
2015
Q2
$196K Buy
19,162
+4,243
+28% +$46.9K ﹤0.01% 5249
2015
Q1
$139K Sell
14,919
-920
-6% -$8.23K ﹤0.01% 5391
2014
Q4
$111K Buy
15,839
+15,403
+3,533% +$88.1K ﹤0.01% 5505
2014
Q3
$2K Buy
+436
New +$2.5K ﹤0.01% 6458

Morgan Stanley's FOMX Position: Q1 2020 in Review

Morgan Stanley sold out of Foamix Pharmaceuticals Ltd. Ordinary Shares (FOMX) in Q1 2020, closing a stake of 1,407,948 shares — an estimated $4.69M sold.

Morgan Stanley first reported a position in FOMX in Q3 2014 and held it in 19 quarters. The position peaked at $4.69M in Q4 2019. 3 funds tracked by Wall St. Rank hold FOMX as of Q1 2020.

  • Morgan Stanley reported no remaining Foamix Pharmaceuticals Ltd. Ordinary Shares position as of Q1 2020 after selling out during the quarter.
  • Morgan Stanley sold 1,407,948 Foamix Pharmaceuticals Ltd. Ordinary Shares shares in Q1 2020, an estimated $4.69M.
  • Morgan Stanley first reported a position in Foamix Pharmaceuticals Ltd. Ordinary Shares in Q3 2014 and held it in 19 quarters.
  • Morgan Stanley's Foamix Pharmaceuticals Ltd. Ordinary Shares position peaked at $4.69M in Q4 2019.
  • 3 funds tracked by Wall St. Rank held Foamix Pharmaceuticals Ltd. Ordinary Shares as of Q1 2020.

Based on Morgan Stanley's 13F filing for Q1 2020, filed 15 May 2020.